Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Pulmonary Alveolar Proteinosis, Acquired MeSH Supplementary Concept Data 2026


MeSH Supplementary
Pulmonary Alveolar Proteinosis, Acquired
Unique ID
C567049
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C567049
Entry Term(s)
Pulmonary Alveolar Lipoproteinosis, Acquired
Pulmonary Alveolar Proteinosis, Autoimmune
Registry Numbers
0
Heading Mapped to
*Autoimmune Diseases
*Pulmonary Alveolar Proteinosis
Frequency
45
Note
There are 3 clinically distinct forms of pulmonary alveolar proteinosis: hereditary (usually congenital), secondary, and acquired. The acquired form is the most common form, accounting for approximately 90% of cases. The mean age at diagnosis is 39 years and it is associated with smoking in 72% of cases. Secondary pulmonary alveolar proteinosis is associated with functional impairment or reduced numbers of alveolar MACROPHAGES, as occurs in some hematologic cancers, IMMUNOSUPPRESSION, inhalation of inorganic dust or toxic fumes, and certain infections. Congenital pulmonary alveolar proteinosis is a rare, severe, often fatal disorder of newborns associated with PULMONARY SURFACTANT metabolism dysfunction caused by mutations in genes involved in surfactant metabolism. OMIM: 610910
Date Introduced
2012/11/05
Last Updated
2015/09/27
Pulmonary Alveolar Proteinosis, Acquired Preferred
page delivered in 0.005s